Canasa and Entocort ec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Canasa and Entocort ec. Common interactions include tremor among females and injection site erythema among males.

The phase IV clinical study analyzes what interactions people who take Canasa and Entocort ec have. It is created by eHealthMe based on reports of 22 people who take Canasa and Entocort ec from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Jun, 06, 2022

22 people who take Canasa and Entocort ec together, and have interactions are studied.


What is Canasa?

Canasa has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 1,536 Canasa users for its effectiveness, alternative drugs and more.

What is Entocort ec?

Entocort ec has active ingredients of budesonide. It is often used in crohn's disease. eHealthMe is studying from 3,092 Entocort ec users for its effectiveness, alternative drugs and more.

Number of Canasa and Entocort ec reports submitted per year:

Canasa and Entocort ec drug interactions.

Common Canasa and Entocort Ec drug interactions by gender *:

female:

  1. Tremor
  2. Vomiting
  3. Aphagia
  4. Bronchitis
  5. Cardiac disorder
  6. Cardiac failure congestive
  7. Dizziness
  8. Epistaxis
  9. Gastric disorder
  10. Hernia

male:

  1. Injection site erythema
  2. Injection site induration
  3. Injection site pain
  4. Injection site papule
  5. Injection site reaction
  6. Injection site warmth

Common Canasa and Entocort Ec drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Fatigue

30-39:

  1. Interstitial granulomatous dermatitis
  2. Anxiety
  3. Drug exposure during pregnancy
  4. Emotional distress
  5. Pain
  6. Pulmonary embolism
  7. Stress

40-49:

  1. Vomiting
  2. Aphagia
  3. Bronchitis
  4. Cardiac disorder
  5. Cardiac failure congestive
  6. Dizziness
  7. Epistaxis
  8. Gastric disorder
  9. Hernia
  10. Hip fracture

50-59:

  1. Tremor
  2. Infusion related reaction
  3. Lupus-like syndrome
  4. Anaemia
  5. Blood magnesium decreased
  6. Chest pain
  7. Hypotension
  8. Injection site pain
  9. Myalgia
  10. Pain in extremity

60+:

  1. Fistula
  2. Injection site erythema
  3. Injection site induration
  4. Injection site papule
  5. Injection site reaction
  6. Injection site warmth

Common conditions people have *:

  1. Stress And Anxiety: 2 people, 9.09%
  2. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Canasa and Entocort ec?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Canasa and Entocort ec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Canasa interactions:

Browse all interactions between Canasa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Entocort ec interactions:

Browse all interactions between Entocort ec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine and budesonide (the active ingredients of Canasa and Entocort ec, respectively), and Canasa and Entocort ec (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Canasa and Entocort ec.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: